- Home
- Publications
- Publication Search
- Publication Details
Title
Lenvatinib: A Review in Hepatocellular Carcinoma
Authors
Keywords
-
Journal
DRUGS
Volume 79, Issue 6, Pages 665-674
Publisher
Springer Nature
Online
2019-04-16
DOI
10.1007/s40265-019-01116-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
- (2019) Masahiro Kobayashi et al. JOURNAL OF GASTROENTEROLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Evaluation Of The Disease-Specific Items On The Eortc In Hepatocellular Carcinoma Patients Treated With Lenvatinib Or Sorafenib
- (2018) S Hudgens et al. VALUE IN HEALTH
- Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
- (2018) Masahiro Matsuki et al. Cancer Medicine
- Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families
- (2018) Xiao-xiao He et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis
- (2018) Atsushi Hiraoka et al. Cancer Medicine
- AASLD guidelines for the treatment of hepatocellular carcinoma
- (2017) Julie K. Heimbach et al. HEPATOLOGY
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
- (2017) Masao Omata et al. Hepatology International
- Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses
- (2017) Toshiyuki Tamai et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Detrimental Impact of Toxicity on Quality of Life In Hepatocellular Carcinoma Patients Treated with Lenvatinibor Sorafenib
- (2017) S Hudgens et al. VALUE IN HEALTH
- Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer
- (2016) Anubha Gupta et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
- (2016) Kenji Ikeda et al. JOURNAL OF GASTROENTEROLOGY
- Lenvatinib: A Review in Refractory Thyroid Cancer
- (2016) James E. Frampton Targeted Oncology
- A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
- (2015) Shinji Nakamichi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
- (2015) M. Ikeda et al. CLINICAL CANCER RESEARCH
- Lenvatinib: First Global Approval
- (2015) Lesley J. Scott DRUGS
- Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers
- (2014) Robert C. Shumaker et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults
- (2014) Robert C. Shumaker et al. CLINICAL DRUG INVESTIGATION
- Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers
- (2014) Robert Shumaker et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas
- (2014) Anne-Charlotte Dubbelman et al. INVESTIGATIONAL NEW DRUGS
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
- (2013) Kiyoshi Okamoto et al. CANCER LETTERS
- Hypertension and proteinuria: a class-effect of antiangiogenic therapies
- (2008) Vincent Launay-Vacher et al. ANTI-CANCER DRUGS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search